Ā | To ... (M: Mezavant cohort; A: Asacol cohort) | |||||||
---|---|---|---|---|---|---|---|---|
From ... | 1st line | 1st line increased dosage | 2nd line | Failure/relapse | Surgery | Post surgery | Remission | Death |
Active UC: 1st line | Ā | M: 59.5% A: 67.4% | Ā | Ā | Ā | Ā | M: 40.5% A: 32.6% | 0.0%** |
Active UC: 1st line increased dosage | Ā | Ā | M: 38.5% A: 39.0% | Ā | Ā | Ā | M: 61.5% A: 60.0% | 0.0%** |
Active UC: 2nd line | Ā | Ā | Ā | M: 32.0% A: 32.0% | Ā | Ā | M: 68.0% A: 68.0% | 0.0%** |
Active UC: Failure/relapse | Ā | Ā | Ā | Ā | M: 25.8% A: 25.8% | Ā | M: 74.2% A: 74.2% | 0.0%** |
Surgery | Ā | Ā | Ā | Ā | Ā | M: 97.9% A: 97.9% | Ā | M: 2.1% A: 2.1% |
Post surgery | Ā | Ā | Ā | Ā | Ā | M: 100.0% A: 100.0% | Ā | 0.0%** |
Remission | M: 6.5%* A: 9.2%* | Ā | Ā | Ā | Ā | Ā | M: 93.5% A: 90.8% | 0.0%** |
Death | Ā | Ā | Ā | Ā | Ā | Ā | Ā | M: 100.0% A: 100.0% |